Skip to Content

'
Jason Westin

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

My research focus is on improving therapy and outcomes for patients with lymphoma.

 

My specific research interests include:

  1. Diffuse Large B-cell Lymphoma
  2. Development of systems to identify novel, optimal therapeutic combinations
  3. Development of methods to pair these combinations to the correct patients
  4. Drug synergy, additivity, and antagonism
  5. Scale free networks and their role in cancer therapy

 

Education & Training

Degree-Granting Education

2002 University of Florida, Gainesville, FL, MD, elected to AOA, Medicine
1998 University of Florida, Gainesville, FL, BS, Cum Laude, Microbiology

Postgraduate Training

6/2011-6/2012 Research Fellowship, Advanced Scholar - Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, R. Eric Davis
7/2010-6/2011 Chief Fellow, M.D. Anderson Cancer Center, Houston, TX
7/2008-6/2011 Clinical Fellowship, Hematology/Oncology, M.D. Anderson Cancer Center, Houston, TX
6/2002-5/2005 Clinical Residency, University of North Carolina, Chapel Hill, NC

Board Certifications

11/2011 ABIM Medical Oncology
8/2005 ABIM Internal Medicine

Experience/Service

Academic Appointments

Instructor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2011-6/2012
Instructor, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-6/2008
Assistant Professor, Division of Internal Medicine, The University of North Carolina, Chapel Hill, NC, 6/2005-9/2006

Honors and Awards

2012-2013 American Society of Clinical Oncology Young Investigator Award
2011 American Society of Hematology Clinical Research Training Institute
2010-present Paul Calabresi Career Development Award in Clinical Oncology, M.D. Anderson
2010 Janice Davis Singletary Fellowship for Lymphoma, M.D. Anderson
2002 Alpha Omega Alpha Medical Honor Society

Professional Memberships

DLBCL Clinical Trial Team, MD Anderson Cancer Center Lymphoma Department
Member, 7/2010-present
Lymphoma Informatics Committee
Chair, 4/2013-present
New Drug Development Team, MD Anderson Cancer Center Lymphoma Department
Member, 1/2013-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. e-Pub 5/7/2013. PMID: 23488661.
2. Westin JR, Kurzrock R. It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. Mol Cancer Ther 11(12):2549-55, 12/2012. e-Pub 11/30/2012. PMID: 23204432.
3. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk. e-Pub 12/2012. PMID: 23276888.
4. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. Case Report Med 2012:457908, 2012. e-Pub 7/2/2012. PMCID: PMC3395413.
5. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol 2:188, 2012. e-Pub 12/11/2012. PMID: 23248775.
6. Davis RE, Westin JR. Vive la resistance: stem cells in mantle cell lymphoma. Leuk Lymphoma 52(6):944-5, 6/2011. e-Pub 4/2011. PMID: 21463111.
7. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 11/3/2011. PMCID: PMC3216266.
8. Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma 51(1):161-3, 1/2010. PMID: 19863175.
9. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep 4(4):218-24, 10/2009. PMID: 20425411.

Abstracts
1. Chu F., Westin J., Zhang M, Feng L, Baladandayuthapani V, Wang Z., Allen R, Wallace M., Vence LM, Radvanyi L, Kwak LW, Rotem-Yehudar R, Davis RE, and Neelapu SS. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma treated with CT-011, a Humanized anti-PD-1 Monoclonal. Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 162, 2012.
2. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 793, 2012.
3. Oki Y., Westin J., Fowler N, Neelapu S, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Rodriguez MA, Orlowski RZ, Wang M, Ouzanian S. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 3707, 2012.
4. Westin J., Fu S., Hong D., Helgason T., Culotta C., Angelo L., Ouyang F., Westin S., Kurzrock R. Validation of the Phase 0 Concept J Clin Oncol 29: 2011 (suppl; abstr TPS143), 2011.
5. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Prior to Receiving Frontline Therapy. Presented at the 2010 14th Annual International Congress on Hematologic Malignancies, 2010.
6. Westin J., Chu F., Foglietta,M., Rodionov G., Rotem-Yehudar R., Neelapu SS. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no. 15_suppl TPS305, 2010.
7. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no. 15_suppl 9103, 2010.
8. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Zoledronic acid treatment of frontline lymphoma patients; Prevention of bone loss. Poster presentation at the Hematologic Malignancies 2010 - Sixth International Conference, 2010.
9. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response Blood (ASH Annual Meeting Abstracts) 2009 114: Abstract 3922, 2009.
10. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy Clin Lymphoma Myeloma. 2009 Dec;9(6):E30, 2009.
11. Westin J., Saliba R., de Lima M, Alousi A., Hosing C., Qazilbash M, Khouri I., Shpall E., Champlin R. Couriel, D. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD) Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 5015, 2007.

Book Chapters
1. Westin J., Kantarjian H., Kurzrock R. Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes. In: 2012 ASCO Educational Book, ASCO Annual Meeting, 2012.
2. Westin J., Romaguera J. Multidisciplinary Approach to Cancer: A Medical Oncologists View. In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon, 2010.
3. Westin J., Hagemeister R., Fanale M. Hodgkin Lymphoma. In: The MD Anderson Manual of Medical Oncology. Second edition, 2009.

Grant & Contract Support

Title: Paul Calabresi K12 Career Development Award in Clinical Oncology
Funding Source: NIH/NCI
Role: Co-Principal Investigator
 
Title: Loan Repayment Clinical Research - Extramural
Funding Source: NIH/NCI
Role: Co-Principal Investigator
 
Title: Developing Combination Chemotherapy and Targeting Resistance in B-Cell Lymphoma
Funding Source: Southwest Oncology Group
Role: Co-Principal Investigator
Principal Investigator: R. Eric Davis
 
Title: ASCO YIA Targeting Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma: Defining the Role of the PI3K/Akt/mTOR Pathway
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator

Last updated: 2/5/2013